⏳ Day 3 at BIO Japan 2025 | LOTTE BIOLOGICS
バイオジャパン2025 3日目｜ロッテバイオロジクス

📍 PACIFICO Yokohama

Thank you for a fantastic final day.
In today’s session, our CEO James Park presented “Redefining Pharma’s Future: CDMO Strategies for Next-Gen ADC.”

📌 Key takeaways:
- Geopolitical/regulatory shifts are reshaping supply-chain strategies—requiring U.S.-based redundancy.
- Biotech funding pressure is intensifying—demanding faster, lower-risk development execution.
- Advanced modalities are evolving—ADCs, bispecifics, and other antibody-derived formats now dominate pipeline growth.

LOTTE BIOLOGICS offers tailored CDMO solutions to clients, helping to overcome these hurdles in getting treatments to patients.

Powered by a dual-site model—from Syracuse, NY and Songdo, South Korea—we offer built-in redundancy, flexibility, and room to scale complex biologics with confidence.

Let’s keep the momentum; reach out via our [Contact Us] page to continue the conversation
👉 https://lnkd.in/gaD8P-3y 

ご来場いただいた皆さまに心より御礼申し上げます。

hashtag#BIOJapan2025
hashtag#LOTTEBIOLOGICS hashtag#CDMO hashtag#ADC hashtag#mAbs hashtag#Biomanufacturing hashtag#Partnering hashtag#Seminar